Florquinitau F18
- Generic Name
- Florquinitau F18
Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau
Phase 1
Not yet recruiting
- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- Device: Neuronavigation-guided single-element focused ultrasound transducerOther: Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agentsRadiation: Positron Emission Tomography (PET)Diagnostic Test: Blood drawDevice: UR5eDiagnostic Test: Urine test
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 6
- Registration Number
- NCT06600880
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Tammie L. S. Benzinger, MD, PhD
- Target Recruit Count
- 200
- Registration Number
- NCT04104659
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein
Early Phase 1
Completed
- Conditions
- Alzheimer DiseaseHealthy Volunteers
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Invicro
- Target Recruit Count
- 10
- Registration Number
- NCT03071224
- Locations
- 🇺🇸
Invicro, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath